Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Single-agent gemcitabine in patients with resistant small-cell lung cancer
Autore:
van der Lee, I; Smit, EF; van Putten, JWG; Groen, HJM; Schlosser, NJJ; Postmus, PE; Schramel, FMNH;
Indirizzi:
St Antonius Hosp, Dept Pulmonol, NL-3430 EM Nieuwegein, Netherlands St Antonius Hosp Nieuwegein Netherlands NL-3430 EM euwegein, Netherlands Vrije Univ Amsterdam, Univ Hosp, Dept Pulmonol, Amsterdam, Netherlands Vrije Univ Amsterdam Amsterdam Netherlands onol, Amsterdam, Netherlands Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands Univ Groningen Hosp Groningen Netherlands monol, Groningen, Netherlands Univ Utrecht Hosp, Dept Pulmonol, Utrecht, Netherlands Univ Utrecht Hosp Utrecht Netherlands pt Pulmonol, Utrecht, Netherlands
Titolo Testata:
ANNALS OF ONCOLOGY
fascicolo: 4, volume: 12, anno: 2001,
pagine: 557 - 561
SICI:
0923-7534(200104)12:4<557:SGIPWR>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II; CLINICAL-TRIALS; CHEMOTHERAPY; PACLITAXEL; TOPOTECAN; ETOPOSIDE;
Keywords:
gemcitabine; resistant; small-cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Schramel, FMNH St Antonius Hosp, Dept Pulmonol, POB 2500, NL-3430 EM Nieuwegein, Netherlands St Antonius Hosp POB 2500 Nieuwegein Netherlands NL-3430 EM
Citazione:
I. van der Lee et al., "Single-agent gemcitabine in patients with resistant small-cell lung cancer", ANN ONCOL, 12(4), 2001, pp. 557-561

Abstract

Objective: This study was conducted to assess the activity and toxicity ofgemcitabine in patients with resistant small-cell lung cancer (SCLC). Patients and methods: Forty-one patients with limited- or extensive-stage SCLC, who were previously treated with at least one chemotherapeutic regimen and progressed during or within three months of finishing the last regimen, were treated with 1000 mg/m(2) gemcitabine on days 1, 8, and 15 of a four-week cycle. Results: Thirty-eight patients were evaluable for response. Five partial and no complete responses were seen, for an overall response rate of 13% (95% confidence interval (CI): 6%-27%). Time to progression varied from 4 to 20 weeks, with a median of 8 weeks. Median survival was 17 weeks (range 4-84weeks). Hematological toxicity mainly consisted of NCI-CTC grade 3 thrombocytopenia (29% of patients) and, to a lesser extent, grade 3 leukopenia (18% of patients). Non-hematological toxicity was mild, with nausea being the most commonly reported event. Conclusions: Gemcitabine has modest activity in patients with resistant SCLC. There is some non-cross resistance to most agents against SCLC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 02:25:51